Effectiveness of trichostatin a as a potential candidate for anticancer therapy in non-small-cell lung cancer

Annals of Thoracic Surgery

Volumn 81, Issue 3, 2006, Pages 1034-1042

  Mukhopadhyay, Nishit K ^a   Weisberg, Ellen ^b   Gilchrist, David ^b   Bueno, Raphael ^b   Sugarbaker, David J ^b   Jaklitsch, Michael T ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 2; GELSOLIN; PROTEIN P21; PROTEIN P27; TRICHOSTATIN A;

ACETYLATION; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LUNG FIBROBLAST; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; STAINING; STATISTICAL SIGNIFICANCE; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN D1; ENZYME INHIBITORS; GELSOLIN; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; LUNG; LUNG NEOPLASMS;

EID: 32644466859     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2005.06.059     Document Type: Article

References (47)

1. G. Arents, R.W. Burlingame, B.C. Wang The nucleosomal core histone octamer at 3.1 A resolution a tripartite protein assembly and a left-handed superhelix Proc Natl Acad Sci USA 88 1991 10148 10152
2. G. Arents, E.N. Moudrianakis The histone fold a ubiquitous architectural motif utilized in DNA compaction and protein dimerization Proc Natl Acad Sci USA 92 1995 11170 11174
3. W.D. Cress, E. Seto Histone deacetylases, transcriptional control, and cancer J Cell Physiol 184 2000 1 16
4. P.A. Marks, R.A. Rifkind, V.M. Richon Histone deacetylases and cancer causes and therapies Nature Rev Cancer 1 2002 194 202
5. A.P. Wolffe Sinful repression Nature 387 1997 16 17
6. H.Y. Kao, C.H. Lee, A. Komarov Isolation and characterization of mammalian HDAC10, a novel histone deacetylase J Biol Chem 277 2002 187 193
7. V.M. Richon, J.P. O'Brien Histone deacetylase inhibitors a new class of potential therapeutic agents for cancer treatment Clin Cancer Res 8 2002 662 664
8. S. Ali-Si-Ali, A. Polesskaya, S. Filleur CBP/p300 histone acetyl-transferase activity is important for the G1/S transition Oncogene 19 2000 2430 2437
9. L. Srinivasan, K.P. Gopinathan Characterization of RNA polymerase III transcription factor TFIIIC from the mulberry silkworm, Bombyx mori Eur J Biochem 269 2002 1780 1789
10. wafi/cip1, Bcl-xL, ID1, ID2, ID3, CRAB2, GATA-2, hsp86 and TFIID/TAFII31 mRNA in human lung adenocarcinoma cells Biol Chem 381 2000 107 112
11. S.G. Gray, T.J. Ekstrom Effects of cell density and trichostatin A on the expression of HDAC1 and p57Kip2 in Hep 3B cells Biochem Biophys Res Commun 245 1998 423 427
12. C. Van Lint, S. Emilliani, E. Verdin The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation Gene Expr 5 1996 245 253
13. F. Lallemand, D. Courilleau, M. Sabbah Direct inhibition of the expression of cyclin D1 gene by sodium butyrate Biochem Biophys Res Commun 229 1996 163 169
14. D.H. Chung, F. Zhang, F. Chen Butyrate attenuates BCLX(L) expression in human fibroblasts and acts in synergy with ionizing radiation to induce apoptosis Radiat Res 149 1998 187 194
15. D.M. Vigushin, S. Ali, P.E. Pace Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo Clin Cancer Res 7 2001 971 976
16. L. Sambucetti, D. Fischer, S. Zabludoff Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects J Biol Chem 274 1999 34940 34947
17. L. Xu, C.K. Glass, M.G. Rosenfeld Coactivator and corepressor complexes in nuclear receptor function Curr Opin Genet Dev 9 1999 140 147
18. H. Kosugi, M. Towatari, S. Hatano Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia a new approach to anti-leukemia therapy Leukemia 13 1999 1316 1324
19. M. Suenaga, H. Soda, M. Oka Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells Int Cancer J 97 2002 621 625
20. W.G. Zhu, R.R. Laksmanan, M.D. Beal, G.A. Otterson DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitor Cancer Res 61 2001 1327 1333
21. J.B. Maxhimer, R.M. Reddy, J. Zuo Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (Trichostatin A) and protein kinase C inhibitor (Calphostin C) J Thorac Cardiovasc Surg 129 2005 53 63
22. F.F. Ferrara, F. Fazi, A. Bianchini Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia Cancer Res 61 2001 2 7
23. Y. Hoshikawa, H.J. Kwan, M. Yoshida Trichostatin A induces morphological changes and gasoline expression by inhibiting histone deacetylase in human carcinoma cell lines Exp Cell Res 214 1994 189 197
24. X. Li, M. Yoshida, T. Beppu, R. Lotan Modulation of growth and differentiation of human colon carcinoma cells by histone deacetylase inhibitory trichostatin Int J Oncol 8 1996 431 437
25. L.M. Mielnicki, A.M. Ying, K.L. Head Epigenetic regulation of gasoline expression in human breast cancer cells Exp Cell Res 249 1999 161 176
26. I. Matsumura, J. Ishikawa, K. Nakajima Thrombopoietin-induced differentiation of a human activation of p21 (WAF1/Cip1) by STAT5 Mol Cell Biol 17 1997 2933 2943
27. S. Ogawa, N. Hirano, N. Sato Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias Blood 84 1994 2431 2435
28. J. Hu, N.H. Colburn Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding Mol Cancer Res 3 2005 100 109
29. W. Wharton, J. Savell, W.D. Cress Inhibition of mitogenesis in Balb/c-3T3 cells by Trichostatin A Multiple alterations in the induction and activation of cyclin-cyclin-dependent kinase complex J Biol Chem 275 2000 33981 33987
30. M.S. Kim, H.J. Kwon, Y.M. Lee Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes Nat Med 7 2001 437 443
31. M. Tanaka, L. Mullauer, Y. Ogiso Gelsolin a candidate for suppressor of human bladder cancer Cancer Res 55 1995 3228 3232
32. A.D. Thor, S.M. Edgerton, S. Liu Gelsolin as a negative prognostic factor and effector of motility in erb-2-positive epidermal growth factor receptor-positive breast cancers Clin Cancer Res 7 2001 2415 2424
33. J. Yang, D. Tan, H.L. Asch Prognostic significance of gelsolin expression level and variability in non-small-cell lung cancer Lung Cancer 46 2004 29 42
34. W. Witke, A.H. Sharp, H.H. Hartwig Hemostatic, inflammatory, and fibroblast responses are blunted in mice lacking gelsolin Cell 81 1995 41 51
35. M. Chellaiah, N. Kizer, M. Silva Gelsolin deficiency blocks podosome assembly and produces increased bone mass and strength J Cell Biol 148 2000 665 678
36. W. Zhang, J.J. Bieker Acetylation and modulation of erythroid Kruppel-like factor (EKLF) activity by interaction with histone acetyltransferases Proc Natl Acad Sci USA 95 1998 9855 9860
37. K. Peltonen, T.M. Kiviharju, P.M. Jarvinen, M. Laiho Melanoma cell lines are susceptible to histone deacetylase inhibitor TSA provoked cell cycle arrest and apoptosis Pigment Cell Res 18 2005 196 202
38. T. Vanhaecke, P. Papeleu, G. Elaunt, V. Rogiers Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents toxicological point of view Curr Med Chem 11 2004 1629 1643
39. P.A. Marks, V.M. Richon, R.A. Rifkind Histone deacetylase inhibitors inducers of differentiation or apoptosis of transformed cells J Natl Cancer Inst 92 2000 1210 1216
40. R.W. Johnstone Histone-deacetylase inhibitors novel drugs for the treatment of cancer Nat Rev 1 2002 287 299
41. P.A. Marks, V.M. Richon, R. Breslow, R.A. Rifkind Histone deacetylase inhibitors as new cancer drugs Curr Opin Oncol 13 2001 477 483
42. L.M. Butler, D.B. Agus, H.I. Scher Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostatic cancer cells in vitro and in vivo Cancer Res 60 2000 5165 5170
43. N. Saunders, A. Dicker, C. Popa Histone deacetylase inhibitors as potential anti-skin cancer agents Cancer Res 59 1999 399 404
44. M. Takakura, S. Kyo, Y. Sowa Telomerase activation by histone deacetylase inhibitor in normal cells Nucl Acids Res 29 2001 3006 3011
45. L. Qiu, M. Kelso, C. Hansen Anti-tumor activity in vitro and in vivo of selective differentiating agents containing hydroxamate Br J Cancer 80 1999 1252 1258
46. C. Nervi, U. Borello, F. Fazi Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity Cancer Res 61 2001 1247 1249
47. J.H. Choi, S.W. Oh, M.S. Kang Trichostatin A attenuates airway inflammation in mouse asthma model Clin Exp Allergy 35 2005 89 96